---
title: "NovoCure Q1 2026 earnings preview"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284613352.md"
description: "NovoCure (NVCR) will announce its Q1 earnings on April 30th, with a consensus EPS estimate of -$0.51, reflecting a 64.5% year-over-year decline, and a revenue estimate of $167.77 million, indicating an 8.2% year-over-year increase. The company has a track record of beating EPS and revenue estimates 63% of the time over the past two years."
datetime: "2026-04-29T16:31:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284613352.md)
  - [en](https://longbridge.com/en/news/284613352.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284613352.md)
---

# NovoCure Q1 2026 earnings preview

NovoCure (NVCR) is scheduled to announce Q1 earnings results on Thursday, April 30th, before market open. The consensus EPS Estimate is -$0.51 (-64.5% Y/Y) and the consensus Revenue Estimate is $167.77M (+8.2% Y/Y). Over the last 2 years, NVCR has beaten EPS estimates 63% of the time and has beaten revenue estimates 63% of the time. Over the last 3...

### Related Stocks

- [NVCR.US](https://longbridge.com/en/quote/NVCR.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership](https://longbridge.com/en/news/286787574.md)
- [Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST](https://longbridge.com/en/news/286893528.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)